Warning: The NCBI web site requires JavaScript to function. more...
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K.
Breast Cancer Res. 2008;10(5):R79. Epub 2008 Sep 22.
Related citations
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
Borgquist S, Djerbi S, Pontén F, Anagnostaki L, Goldman M, Gaber A, Manjer J, Landberg G, Jirström K.
Int J Cancer. 2008 Sep 1;123(5):1146-53.
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
Brennan DJ, Laursen H, O'Connor DP, Borgquist S, Uhlen M, Gallagher WM, Pontén F, Millikan RC, Rydén L, Jirström K.
Breast Cancer Res. 2011 Jan 31;13(1):R12.
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H, Levesque MA, Clark GM, Diamandis EP.
Br J Cancer. 1999 Oct;81(3):490-5.
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.
Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.
Brennan DJ, Brändstedt J, Rexhepaj E, Foley M, Pontén F, Uhlén M, Gallagher WM, O'Connor DP, O'Herlihy C, Jirstrom K.
BMC Cancer. 2010 Apr 1;10:125.
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. Epub 2008 Sep 23.
A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
Breast Cancer Res. 2008;10(5):R88. Epub 2008 Oct 17.
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.
Med Oncol. 2009 Dec;26(4):480-90. Epub 2009 Jan 7.
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn JG.
Br J Cancer. 1999 Feb;79(5-6):888-94.
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Lancet. 2004 Sep 4-10;364(9437):858-68.
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
Jögi A, Brennan DJ, Rydén L, Magnusson K, Fernö M, Stål O, Borgquist S, Uhlen M, Landberg G, Påhlman S, Pontén F, Jirström K.
Mod Pathol. 2009 Dec;22(12):1564-74. Epub 2009 Sep 4.
Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.
van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ.
Br J Cancer. 1996 Jul;74(1):78-85.
Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
Cameron DA, Gregory WM, Bowman A, Anderson ED, Levack P, Forouhi P, Leonard RC.
Br J Cancer. 2000 Jul;83(1):98-103.
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, Lee JE, Shin HJ, Hwang KT, Hwang SE, Kim SW, Noh DY.
BMC Cancer. 2006 Apr 12;6:92.
Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
Acta Oncol. 2009;48(4):514-21.
Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R; European Organisation for Research and Treatment of Cancer Breast Group; Scottish Breast Cancer Trials Group.
Eur J Cancer. 2007 Jan;43(2):331-40. Epub 2006 Nov 28.
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO.
Breast Cancer Res Treat. 2010 Jan;119(1):53-61. Epub 2009 Feb 10.
Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.
Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R.
J Clin Oncol. 2000 Apr;18(7):1423-31.
Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
Berglund P, Stighall M, Jirström K, Rydén L, Fernö M, Nordenskjöld B, Landberg G.
J Clin Pathol. 2008 Feb;61(2):184-91. Epub 2007 May 4.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on